Regarding combination therapy with SGLT2 inhibitors and other agents such as mineralocorticoid receptor antagonists (MRAs) and glucagon-like peptide-1 receptor agonists (GLP-1RAs): SGLT2 inhibitors have demonstrated significant and clinically relevant reductions in albuminuria, nephropathy progression, doubling of serum creatinine levels, and initiation of renal replacement therapy. The gene discussed is SLC5A2; the disease is Nephropathy.